Shots:
Amberstone Biosciences has entered into a collaboration & license agreement with Henlius Biotech to advance conditionally activated T-cell engagers for the treatment of solid tumors
As per the deal, Amberstone will use its T-MATE platform to generate preclinical candidates against ~2 Henlius-selected targets, while Henlius will lead subsequent research, development, manufacturing & global commercialization…
